In addition, ARAF mutation has been discovered in lung cancer, and sorafenib, the RAF-targeted kinase inhibitor, improves the prognosis of advanced lung cancer patients (Imielinski et al., 2014). The gene discussed is ARAF; the disease is lung carcinoma.